As we described above, in CRC it was long known that despite activating mutations in the Wnt pathway that occur early in tumor development, such as APC truncating mutations or β-catenin/CTNNB1 stabilizing mutations, heterogeneous Wnt activity levels can be detected as evidenced by various degrees of nuclear localized β-catenin in individual cancers. The gene discussed is APC; the disease is cancer.